[Therapeutical trial in recovery room (author's transl)].
During a limited period of time, the authors have systematically administered tiapride to all patients in the immediate post-operative phase presenting with: nausea, vomiting, pain. Intravenous injection of a single dose of 400 mg of tiapride produces: a strong anti-emetic action; an inconstant analgesic action, but very interesting for it is not accompanied with adverse effects.
D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D010149:Postoperative Pain / Q000188:drug therapy*; D014839:Vomiting / Q000517:prevention & control*
D000932:Antiemetics; D014150:Antipsychotic Agents; D001549:Benzamides
Essai thérapeutique en salle de réveil.